+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dyslipidemia (Metabolic Disorder) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 411 Pages
  • July 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5402622
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Drugs In Development, 2021, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 32, 23, 24, 3, 34, 14 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Dyslipidemia - Overview
  • Dyslipidemia - Therapeutics Development
Dyslipidemia - Therapeutics AssessmentDyslipidemia - Companies Involved in Therapeutics DevelopmentDyslipidemia - Drug ProfilesDyslipidemia - Dormant ProjectsDyslipidemia - Discontinued ProductsDyslipidemia - Product Development MilestonesAppendix
List of Tables
  • Number of Products under Development for Dyslipidemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Dyslipidemia - Pipeline by 89bio Inc, 2021
  • Dyslipidemia - Pipeline by ABIONYX Pharma SA, 2021
  • Dyslipidemia - Pipeline by AD Pharmaceuticals Co Ltd, 2021
  • Dyslipidemia - Pipeline by Addpharma Inc, 2021
  • Dyslipidemia - Pipeline by Affina Biotechnologies Inc, 2021
  • Dyslipidemia - Pipeline by Afimmune Biopharma Ltd, 2021
  • Dyslipidemia - Pipeline by Akcea Therapeutics Inc, 2021
  • Dyslipidemia - Pipeline by Amarin Corp Plc, 2021
  • Dyslipidemia - Pipeline by Arrakis Therapeutics Inc, 2021
  • Dyslipidemia - Pipeline by Arrowhead Pharmaceuticals Inc, 2021
  • Dyslipidemia - Pipeline by AstraZeneca Plc, 2021
  • Dyslipidemia - Pipeline by AVVA Pharmaceuticals AG, 2021
  • Dyslipidemia - Pipeline by Bio-Thera Solutions Ltd, 2021
  • Dyslipidemia - Pipeline by BioRestorative Therapies Inc, 2021
  • Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, 2021
  • Dyslipidemia - Pipeline by Cadila Healthcare Ltd, 2021
  • Dyslipidemia - Pipeline by Cardax Inc, 2021
  • Dyslipidemia - Pipeline by Celltrion Inc, 2021
  • Dyslipidemia - Pipeline by Celon Pharma SA, 2021
  • Dyslipidemia - Pipeline by Centaurus Therapeutics Inc, 2021
  • Dyslipidemia - Pipeline by Centeer BioTherapeutics Ltd Co, 2021
  • Dyslipidemia - Pipeline by Chong Kun Dang Holdings Corp, 2021
  • Dyslipidemia - Pipeline by CMG Pharmaceutical Co Ltd, 2021
  • Dyslipidemia - Pipeline by Corvidia Therapeutics Inc, 2021
  • Dyslipidemia - Pipeline by CVI Pharmaceuticals US Inc, 2021
  • Dyslipidemia - Pipeline by Daewon Pharmaceutical Co Ltd, 2021
  • Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
  • Dyslipidemia - Pipeline by Daiichi Sankyo Co Ltd, 2021
  • Dyslipidemia - Pipeline by Delivra Corp, 2021
  • Dyslipidemia - Dormant Projects, 2021
  • Dyslipidemia - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Dyslipidemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 89bio Inc
  • ABIONYX Pharma SA
  • AD Pharmaceuticals Co Ltd
  • Addpharma Inc
  • Affina Biotechnologies Inc
  • Afimmune Biopharma Ltd
  • Akcea Therapeutics Inc
  • Amarin Corp Plc
  • Arrakis Therapeutics Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • AVVA Pharmaceuticals AG
  • Bio-Thera Solutions Ltd
  • BioRestorative Therapies Inc
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • Cardax Inc
  • Celltrion Inc
  • Celon Pharma SA
  • Centaurus Therapeutics Inc
  • Centeer BioTherapeutics Ltd Co
  • Chong Kun Dang Holdings Corp
  • CMG Pharmaceutical Co Ltd
  • Corvidia Therapeutics Inc
  • CVI Pharmaceuticals US Inc
  • Daewon Pharmaceutical Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Delivra Corp
  • Dicerna Pharmaceuticals Inc
  • DongKoo Bio & Pharma Co Ltd
  • Eccogene (Shanghai) Co Ltd
  • Eli Lilly and Co
  • Elyson Pharmaceutical Co Ltd
  • Gilead Sciences Inc
  • Golden Biotechnology Corp
  • Guangzhou Jiayue Pharmaceutical Technology Co Ltd
  • Halo Therapeutics Ltd
  • Handok Inc
  • Hanlim Pharm Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • HK inno.N Corp
  • Huons Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • Inovio Pharmaceuticals Inc
  • Japan Tobacco Inc
  • Jeil Pharmaceutical Co Ltd
  • Jenrin Discovery Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • JW Pharmaceutical Corp
  • Kolmar Pharma Co Ltd
  • Korea United Pharm Inc
  • Kotobuki Pharmaceutical Co Ltd
  • Kowa Co Ltd
  • Kuhnil Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Kyung Dong Co Ltd
  • Les Laboratoires Servier SAS
  • Liid Pharmaceuticals Inc
  • LipimetiX Development Inc
  • Lyndra Therapeutics Inc.
  • Matinas BioPharma Holdings Inc
  • MD Healthcare Inc
  • Micelle BioPharma Inc
  • Mochida Pharmaceutical Co Ltd
  • Navipharm Co Ltd
  • NewAmsterdam Pharma BV
  • Nippon Chemiphar Co Ltd
  • Nissan Chemical Corp
  • NorthSea Therapeutics BV
  • NovalGen Ltd
  • Novartis AG
  • Nubiyota LLC
  • NuSirt Biopharma Inc
  • Omeros Corp
  • Orient Pharma Co Ltd
  • Pfizer Inc
  • Pharmena SA
  • Regeneron Pharmaceuticals Inc
  • Sequor Pharmaceuticals LLC
  • Shanghai Junshi Bioscience Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Sirnaomics Inc
  • SJT Molecular Research SL
  • Staten Biotechnology BV
  • Suzhou Ribo Life Sciences Co Ltd
  • Sveikatal Inc
  • Synokem Pharmaceuticals Ltd
  • Tetranov International Inc
  • Torrent Pharmaceuticals Ltd
  • Viking Therapeutics Inc
  • Whan In Pharm Co Ltd
  • Yooyoung Pharm Co Ltd
  • Yungjin Pharm Co Ltd